June 17, 2020
Merck and Pfizer’s SGLT2 Inhibitor STEGLATROTM (ertugliflozin) Meets Primary Endpoint in VERTIS CV Trial for Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
Results Presented at the American Diabetes Association’s Virtual 80th Scientific Sessions KENILWORTH, N.J. & NEW YORK–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK),…